InnoCare Pharma
2024630
20246302023630
20242023
419,738377,549(60,140)(76,072)359,598301,477111,356131,265(157,153)(191,208)(420,822)(358,130)(91,511)(87,299)(33,059)(179,150)(267,952)(429,184)
(242,992)(206,261)2024
20231231
*7,992,2228,287,136
2023630320.7
30.0%2024630417.0MZL
20242023
48.8%2023630377.5
11.2%2024630419.7
2023
2023630301.519.3%2024630359.62024630
85.7%202363079.9%5.8
*
2023630636.65.2%2024630
669.5(i)2023630191.234.02024630157.2
(ii)62.72024630420.8
(iii)2023630
87.34.8%2024630
91.5
2023630429.237.6%2024630268.0
202463079.9
20242023
(267,952)(429,184)25,308178,005
(348)44,918
(242,992)(206,261)
202413
(R&D)
ICP-248ICP-B02ICP-490ICP-B05NHLMM
2024
?BTK2024630
417.02023320.7
30.0%
1)
CLL/SLL
MCL
MZLNRDL
2) MZLBTK
MZLBNHL2023DOI:10.1002/ajh.27058
2024CSCOMZL3)
4)
DOT
2024
MZLNDA20234
NMPAMZLBTK
IRCORR58.9%12PFSOS82.8%91%
MCLII
FDAFDANDA MCDBDLBCL
1LIII
R-CHOPR-CHOPMCDDLBCL44
ICP-B04CD19(Minjuvi
?
) 20246BLA
CDEASCT
DLBCLDLBCL2025BLA2022
BLAASCTDLBCLDLBCL
ASCTDLBCLDLBCL
CSCOASCTDLBCL
ICP-248
ICP-248B2BCL-2
II/IIIICP-2481L CLL/SLL20245
40ICP-248ICLL/SLLMCLNHL
BCL-2PK4728100mg25125mg3QDBTKiBTKiNHLORR71.4%78.5%BTKBTKiMCLORR71.4%IND
20241AMLINDCDEICP-B02 (CM355)
ICP-B02CD20CD3I/II
ICP-B02NHLPK
IVSCIVSCICP-B02FLDLBCL15ICP-B02≥6
ORR100%SC11ORR
100.0%(11/11)CRR63.6%(7/11)2DLBCL
CRCRICP-B02ICP-B02
NHLIND
ICP-490 ICP-490
MMNHLIICP-490
PDAiolos (IKZF3)Ikaro (IKZF1)
20239INDCDEICP-490ICP-490MMNHL
ICP-B05 (CM369)
ICP-B05CC8CCR8
(2162.HK)IICP-B05NHL
ICP-B05150NHLICP-B05
DLT3AE
TNHL2024816
63(50%)(PR)
ICP-B05
BT
3.7%
20291,850
2023103iHealthcareAnalyst, Inc.BT
ITP
PoCIII202310
202420252023612ITPIIPoCEHA2023
20244(The American Journal ofHematology)50QD40%
50QDGCIVIG75%6/8BTKITP
SLEIIa
SLESRI-4
IIb
CDE
MSII24
Cmax
50QD80QD24Gd+T1
92.3%MS
T12480QDGd+ T1
TEAEMSICP-332 ICP-3322TYK2
T202312ICP-332
TYK-2ADIIICP-3324AD
EASI
8078.2%
12072.5%16.7%(p<0.0001)ICP-33280120
EASI 50EASI 75EASI 90EASI50%75%90%(IGA) 0/1
EASI 758012064%/64%
EASI 758%(p<0.0001)TRAE
AD IIIICP-332 2024AD III
ICP-332IND20246FDA
ICP-488
ICP-488TYK2TYK2
JH2IL-23IL12IIFN
ICP-488ICP-488I
PKICP-488136ICP-4883-12ICP-488<1.5
ICP-4884ICP-4886PASI
37.5%13.8%p=0.0870alpha0.1PASI50(0%)ICP-488 6QD42%
TEAETRAEICP-488TEAETRAEICP-488
II II20245
2024
ICP-B02 (CM355)
ICP-B02CD20 CD3 TT
BICP-B02SCIVNHLI/II
BB
ICP-B02
IL-17 IL-17
IL-17AIL-17A
IL-17AAIL-17AFIL-17R
ICP-723ICP-189ICP-B05
ICP-723 (Zurletrectinib) NTRK
12ICP-723 II80–90%ORRZurletrectinibTRK
TRKi212IND20237CDE
2025NDA
ICP-189 ICP-189SHP2
IaICP-189
120QDDLTAE3160QDICP-189120ICP-189DUSP6IC
90%DUSP6MAPKICP-189
201PR14
ICP-189ArriVentEGFR
NSCLCI2024380ICP-18980
DLT120ICP-18980
DUSP6ICP-189MAPKICP-192 (Gunagratinib) Gunagratinib
FGFRI
CCAII202312023ASCO-GIgunagratinibIIa
20242.0
MZL
2023
30.0%
2024
2024
1.0
2.0
ICP-248ICP-B02ICP-490ICP-B05
NHL20246CDEASCT
DLBCLBLA2025BLA
ICP-2481L CLL/SLLICP-248AMLINDCDE
BT
B
ITPIIPoCIII
SLEIIaSLE
BTKIIb
NMOSDIICSUHS
TICP-332ADIIPoCICP-488PoCTSLELNIBD
BICP-332ICP-488IL-17T
ICP-723ICP-189ICP-B05
IND
BTK
r/rCLL/SLLr/rMCLr/rMZL1L:CLL/SLL1L:MCDDLBCLICP-B02CD3xCD20ICP-248
NHLBCL2ICP-490
Tafa+LEN, r/rDLBCLCD19
CCR8ICP-B05
1L:MCL
IND???AML
1LCLL/SLL
r/rMCL
IND??
Ia?
| ? |
Ib?
II?
| ? |
*II?
**III?
| ? |
????
NDA
NDA
ICP-022/
ICP-B04/
20201225202012252023421
MM/DLBCL/E3???
| ??? |
MZL??
ICP-248IV&SC
2024?
2024?
2024?2024??у?
????у?????
??
?????
| ????? |
?????
?????
| ????? |
??
BLA?6Д???
ICP-B05
pan-FGFRICP-192/Gunagratinib
pan-TRKICP-723/Zurletrectinib
SHP2ICP-189
CCR8
SLEMS
BTK
ITPNMOSDTYK2 –JH1ICP-332TYK2 –JH2ICP-488
NTRK
Ia?
???
Ib?
| ? |
II?
*II?
| ? |
**III?
OEB??
| OEB?? |
NDA
ICP-022/
+EGFRi
??
?
BTK
?
BTK2022CLL/SLLMCL2024
MZL2023
?
CLL/SLLMCLMZLCSCOBTK
DLBCLpCNSL2024630417.0202363030.0%2024202348.8%330
(i)(ii)MZLBTK(iii)(iv)DOT
ICP-248ICP-B02ICP-490ICP-B05
NHLMM
NHLMM(i)(ii)FDAEMACD19DLBCL(iii)
BCL-2CD20CD3E3CCR8(iv)
1,300
(CLL)(SLL)(r/r CLL/SLL)(MCL)(r/r MCL)NMPA
(MZL)(r/r MZL)MZLBTK
MZL
MZLBNHL8%
10%MZL
MZL20234NMPAMZL
MZLBTK2023616ICML
MZLIRC2014ORR
IV75.9%
24.3IRCORR58.9%DOR34.3
PFS12PFS82.8%OS91%
TRAE12
III(R2)R2MZLASH 2023(Jiadai Xu, Lu-Ya Cheng, Yang Ke, et al. Blood 2023142 (Supplement 1)6146.)MZLMZL103(30%)CR6(60%)PRORR90%13.0
7.824.7mPFS6PFS100%OS2023568
9.63.017.8ORR75% (6/8)1SD1PD
CLL/SLL
IICLL/SLL15080CLL/SLL202362652.4
42.5%ORR93.8%CR30%
1.84DORPFS5250
CLL/SLLBTKCR
AE
MCL
MCLBB
MCL60
MCL
CR
202352BloodBlood Advances
MCLMCL
10620236946.98
CTORR83%
35.8%CR3.8%CRu43.4%PR
DOR25.79PFS24.94OS56.21
MCLIIFDANDAFDABTD
MCL
(OLR)MCLII(Huilai Zhang,Liping Su,Lihong Liu, et al. Blood 2023142 (Supplement 1)736.)21(75.0%)616(76.2%)CR5(23.8%)
PR100%2118
MRD18MRDPB-MRDMRDBMMRDDORmPFS12DORPFS
90.9%92.3%
1L CLL/SLL
IIICLL/SLLIRCPFS
54III1L CLL
1L DLBCL-MCD
DLBCLNHL100
MCD1L DLBCL
IIIR-CHOPR-CHOPMCDDLBCL
40%DLBCL
R-CHOP+X
MCDBNF-KBBTK
TITKCD20NKADCC
R-CHOPMCDDLBCL
20226ASCOR-CHOPMCD DLBCL14MCD DLBCL
1508R-CHOPR-EPOCH6RICER-CHOPR2CRR75%66.67%
MCDDLBCLMCDDLBCL
pCNSLEHA 2023
pCNSLII
pCNSLND pCNSL
ORRpCNSLpCNSL
2022ND pCNSLCNSLND pCNSLORR88.9%100%CR53.9%61.8%ND pCNSL
CRmPFS6PFS
63.6%100%
60%CNSLORR60%
86.7%CRmPFS9.83mPFS
BCRMYD88
MOA
BBBBBB15021.6BBB58.6%
pCNSL
ICP-248BCL-2
BTKBCLL/SLLMCLCLL
CLLBTKPFS
BTKOSBTK
uMRD
BCL-2BCL-2B
BCL-2BTKCLL/SLLMCL
CLL/SLL
ICP-248BCL-2CLL/SLLMCL
ICP-B04 ()
IIASCTDLBCLBLA20246NMPACDE
2025IIDLBCLIRCORRDCRDORPFSTTPTTROSEHA 20242024129IRCORR73.1%32.7%CR40.4%
PRORR69.2%34.6%CR34.6%PR
ASCTDLBCLDLBCLDLBCLB-NHLCD19B-NHLCSCOASCTDLBCL
BLAASCTDLBCL
DLBCL
ICP-248ICP-248B2BCL-2BCL-2BCL-2
ICP-248ICP-248DDIBLC2
ICP-248BCL-2
ICP-248CLL/SLLNHL
ICP-248IIICP-248B
CLL/SLLMCLNHLBCL-2ICP-248
28100mg25125mg3QDBTKiBTKiNHLORR71.4%78.5%BTKiMCLORR71.4%
ICP-24820241FDAIND20241
AMLINDCDEBCL-2BTKII/IIIICP-2481L CLL/SLL20245
ICP-B02 (CM355)
ICP-B02
BCD20CD3
TDCCICP-B02IVSCIVSCFLDLBCL15ICP-B02≥6ORR100%SC11
ORR100.0% (11/11)CRR63.6% (7/11)2DLBCLCR
ICP-B02NHL
IND20246CDE
0.5/1.5/6
ICP-B02BICP-B02SCIVNHLI/IIB
CRCD19CD20BBB
ICP-B02
ICP-490ICP-490CereblonCRBNE3
IMiDTPD
CRL4CRBN E3ICP-490IKZF1IkarosIKZF3Aiolos
ICP-490MMDLBCL
ICP-490CRBNICP-490ADCCCD38daratumumab
20234182023AACRICP-490
ICP-490MMNHLDLBCL
IC
ICP-490
ICP-490ICP-490MMDLBCLICP-490ICP-490IL-2BCD38daratumumabMMNHL
ICP-490BTK
MMIICP-490
MRICP-490PDAiolos (IKZF3)Ikaro (IKZF1)20239INDCDEICP-490ICP-490
MM
ICP-B05 (CM369)
ICP-B05C-C8CCR8
CCR8TMETTregsICP-B05CCR8TregsADCC
TregsTMEICP-B05
TregsTregs
TregsICP-B05
IICP-B05NHLICP-B05
150NHLICP-B05DLT3TRAEPK
TNHL20248
3(50%)(PR)
ICP-B05BT
BT
AD:
LN:
ITPMSNMOSD
CSU
AD
LNIBDSLE
ICP-332(TYK2i-JH1)ICP-488(TYK2i-JH2)T
(BTKi)
B
| IBD: | ||
IL-17i
SLE:
ITP:
NMOSD:
CSU:
CNSB
ITPPoCGC/IVIG
2023IIISLEIIaSLE
BTKIIb
IINMOSDCSUHS
TTYK2ICP-332ICP-488TADSLELNCDUC
BICP-332ICP-488T
B—
BTKTECB
BCRB
BTKBTK
ITP
ITP
ITP
T
ITP100,00023.6100,0009.5
CD20
BTKBITPB
BTKITPITP
2023ITPII
IIITPIII
5010
/L2742023263350QD30QD
ITP50QD
GC/IVIG36.4%33125040%1561283.3%1210
14246450x10
/L22GCIVIG5075.0%86ITPTRAE12IIITP
BTKITPBTK2023612EHA 2023ITPII
20244(The American Journal of Hematology)
ITPPoC20231020242025
SLEBTKBCRBSLE
SLE
2025SLE1.0620202025
0.7%2030SLE1.09202520300.5%
SLEIIa
SLE1111125080100
IIa
508010012SRI-4
35.7%50.0%61.5%64.3%
GC3C4IIa2022EULAR
5080100
SRI-4 12
N=55
IIaIIb40
IIbSLESLESLE111507548
SRI-4
C3C4dsNDA4850%CDE
IIaSLEBTK
SLE
MS
IIRRMS
MSII2412
Cmax
4T1241250QD80QDGd+ T12492.3%
MS
50QD
PHS , N=115
QD=BID=CI=Gd+ =
50QD50QD50BID80QD
424(95% CI)
6.45 (3.62, 11.52)2.10 (0.62, 7.11)1.08 (0.30, 3.81)0.50 (0.09, 2.74)
67.4 (-22.0, 91.3)83.3 (33.2, 95.8)92.3 (56.5, 98.6)
0.09580.01140.0037
80QDGd+T124
TEAEMS
ALT/AST>8xULN50BID
50QD80QDFDA
2023215
2023215
BMSSPMSPPMS
IIMSOLEMSBTK
NMOSDNMOSD
45-650.445/100,000
4.711
BTKBB
BTKBTKBTKNMOSD
IITII
T— TYK2ICP-332ICP-332TYK2TYK2JAKIL-12/IL-23IFN
T17TH17TH1B
ADICP-332TYK2400JAK2JAK
TYK2ICP-332IBD
PharmaIntelligence12
0.96-22.6%1.2-17.1%2030100Frost & SullivanAD201965.7
203081.71.7%J Allergy Clin Immunol Pract. 2021 Apr9(4)1488–1500
AD33%90%
AD
ICP-332
202312IIPoCII
ICP-332
75AD80mg QD120mg QD 25
ICP-3324ADICP-33280120EASI
EASI 50EASI 75EASI 90EASI≥50%75%90%IGA0/1
*p<0.0001
-16.7%
-80%-70%-60%-50%-40%-30%-20%-10%0%
-78.2%*
-72.5%*
p<0.0001
20%
8%0%10%20%30%40%50%60%70%80%
EASI50EASI75
72%*
64%*64%*90%88%*
*p<0.0001
4EASI 50EASI 75(FAS)4 — (FAS)
ICP-33280QD
ICP-332120QD
ICP-332 80ICP-332 120
(EASI)
(+/- SE)
(%)
ICP-332 80ICP-332 120
(DLQI)
p<0.01
(N=25)
ICP-33280(N=25)
ICP-332120(N=25)D8/W1-3.3(-4.8,-1.9)-6.5(-8.0,-5.1)-6.8(-8.4,-5.3)
ppp
0.00270.0018
D15/W2-2.2(-4.2,-0.2)-8.7(-10.7,-6.7)-7.9(-9.9,-5.9)
<0.00010.0002
D29/W4-1.2(-3.3,0.9)-10.8(-12.8,-8.8)-8.9(-11.0,-6.8)
<0.0001<0.0001
DL
| Q |
I
ICP-332 80ICP-332 120
80120EASI
78.2%72.5%16.7%(p<0.0001)80120EASI 7564%64%
EASI 758%p<0.000180EASI 7556%EASI 9040%IGA0/132%NRS≥456%p<0.01
(NRS) (p<0.01)80120ICP-3322
p<0.01ICP-332ADTRAE
TRAETRAE
II2024AADICP-332 IIAD
ADICP-332III2024AD IIIICP-332IND20246FDA
ICP-488
ICP-488TYK2JH2JH2TYK2
JH2TYK2ICP-488
TYK2TYK2 JH2IL-23IL-121IFNICP-488SLELNIBDICP-488ICP-332TYK2
T23(IL-23)T17(Th17)
2022
1.252%3%
ICP-488IIICP-488
136312ICP-488PKSADPK
?SAD?7.2-11.2
MADPK
0122436486072
-1
(+SD)(ng/mL)
1(N=6)3(N=6)6(N=6)12(N=6)24(N=7)36(N=6)
?6QDCavIC50TYK2
0122436486072
-1
(+SD)(ng/mL)
3QD(N=6)6QD(N=6)12QD (N=6)
ICP-488ISADICP-488IMAD
ICP-488136ICP-4883-12ICP-488<1.5
ICP-488
1Nimbus2022-05-19SDINDI-034858PhaseIbResultsPoster.pdf
0%10%20%30%40%
N=7
ICP-488 6QD
N=12
14%
38%
0%10%20%30%40%50%
ICP-4886QD(5/12)
42%
40%
TAK-27930QD
(2/5)
4ICP-4886PASI
37.5%13.8%p=0.0870alpha0.1PASI 50
(0%)ICP-488 6QD42%TEAETRAEICP-488ICP-488PKIIICP-488II20245
2024
ICP-723
ICP-189NSCLC
ICP-B05
ICP-723 (Zurletrectinib)ICP-723TRK
TRKTRKNTRKTRKTRKICP-723TRKA/B/CTRKAG595RG667CICP-723TRK
20247(British Journal of Cancer)
(Nature)zurletrectinibzurletrectinib
TRK
zurletrectinibTRKATRKBTRKCTRKA G595RTRKA G667C
ZurletrectinibselitrectinibrepotrectinibTRKA G598R/G670A
zurletrectinib(15 mg/kg)
NTRKTRKselitrectinibrepotrectinibzurletrectinib41.566.5104P < 0.05
repotrectinib(15 mg/kg)selitrectinib(30 mg/kg)P=0.0384
0.0022
TRKTRKATRKBTRKC
NTRK1NTRK2NTRK3TRKNTRKNTRKNTRK
NTRK1218ICP-723CDE20237212IND
NTRK12ICP-723 IIICP-723NDA2025NDA
80%-90%ZurletrectinibTRK
TRKi
ICP-189ICP-189SHP2ICP-189SHP2RAS-MAPK
PD-1SHP2
ICP-189ICP-189EGFRKRASMEKPD-1ICP-189ICP-189p-ERKDUSP6 mRNA
IaICP-189120QDDLT3TRAE160QD
ICP-189120ICP-189DUSP6IC
DUSP6MAPKICP-189
201PR142024IaICP-189 IbEGFR
PD-12023714ArriVent BiopharmaArriVentSHP2ICP-189ArriVent
EGFRNSCLCICP-189EGFR
ICP-189EGFRiIb2024380ICP-18980DLT120ICP-18980DUSP6ICP-189MAPK
ICP-189
ICP-192 (Gunagratinib)Gunagratinib
FGFRFGFR
7.1%
GunagratinibFGFR
FGFRgunagratinibFGFR
20231gunagratinibCCAIIa
ICP-19218CCA17
5.57ORR52.9%179DCR
94.1%1716mPFS6.9395% CI5.42—
TRAEFGFRgunagratinibCCAFGR2(52.9%)2023II
50,000
GMPNMPABTK
2022
2023
202530,000
CMC
70,381
202442620232023ESG
ESG2023ESG2028
202310%
100%
192024630
20242023
%%
417,82099.5321,46685.11,9180.556,08314.9
419,738100.0377,549100.0
2023630377.52024630419.72023630
321.530.0%2024630
417.820242023
48.8%2023
20242023
%%
358,44399.7279,33392.71,1550.322,1447.3
359,598100.0301,477100.0
2023630301.519.3%2024630359.62024630
85.7%202363079.9%5.8
2023630131.32024630111.4202363029.217.7202463011.520236
308.37.32024630
1.0
2023630191.22024630157.2
20242023
%%
82,02952.285,63844.893,08759.281,28142.5(31,589)(20.1)10,5425.5
13,6268.713,7477.2
157,153100.0191,208100.0
2023630358.12024630420.8
20242023
%%
162,33838.6146,56140.9143,87034.2117,65432.918,3294.420,8085.837,4048.928,2067.958,88113.944,90112.5
420,822100.0358,130100.0
(i) 146.615.7
162.3
(ii) 117.726.2143.9
(iii) 20.82.518.3
(iv) 28.29.237.4(v) 44.9
14.058.9
202363087.34.8%202463091.5
20242023
%%41,67645.539,77245.612,91314.113,56815.59,80610.711,35113.08,1668.97,1178.26,6417.34,2264.812,30913.511,26512.9
91,511100.087,299100.0
2023630179.2202463033.1
20246301.520236302.1
202363020.3202463010.52023630
11.52023
2024630
2024
20231231
280,677307,638124,881113,994118,381119,095642,941—6,903,6938,224,596
8,070,5738,765,323
5,0005,000117,242134,905669,052667,717
11,27412,00834,18323,2331,274,7941,251,131
2,111,5452,093,994
5,959,0286,671,329
20246305,959.0
6,903.7
280.7124.9
118.4642.9
117.2669.11,274.8
2024
20231231268,816248,942
11,86158,696
280,677307,638
2021
20231231114.02024630124.9(i)2023123139.025.4202463064.4(ii)2023123110.4
4.2202463014.6(iii)2023123162.517.9202463044.6
2024
2023123164,35339,04444,57262,54014,63310,3901,3232,020
124,881113,994
20231231
119.12024630118.4
2024
20231231
693,551—350,406—
1,043,957—
642,941—401,016—
1,043,957—
2024630
642.9401.020231231
2024
20231231
102,521124,20714,68610,432
161991967
117,242134,905
20231231667.72024630669.1
2024
2023123157,79358,19045,78152,99927,44915,25314,74411,85323,76638,336476,336476,33623,18314,750
669,052667,717
2024
20231231
5,0005,00034,18323,233476,336476,3361,274,7941,251,131
33,90026,30039,78143,647294,048305,577
2,158,0422,131,224
202312312,131.220246302,158.0
20231231
280.92024630269.6
20231231759.82024630805.2
20231231293.82024630
296.5
2023123139.0202463036.5
202312315.720246304.1
2023123152.4202463059.0
2024
20231231
3.84.2
20203238.95250,324,0000.0000023,883
2,240.4
2020323H.10
2020415
37,548,00015%
322.59
2021210210,508,00014.45
2021232021210
2022921264,648,2170.000002
11.03
2,778.82
20246307,992.2202312318,287.1
14.075%
20246302024630
2024630
100%21.5%20231231
20.8%
20246301,274.8
294.0
38.9476.3
155.2
76.920235
400.0202463043.9
356.1
2024630
2024630
2024630
201511320203232022921
20246272023
20246272024427
13.51B(1)
20232024427
C.2.1
(i)(ii)
(iii)
C3
202398200
2,198,00011,301,2102024630548,000202427
20241548,00065.63,162,780202421,650,0005.134.548,138,430
2,198,00011,301,210
(1)
(2)(3)
2024420246
6,177,0004.44
5.2229,700,043.6020246301
20246302023
20246302024630
3.10(2)3.21
2024630
2,415.6720246301,560.964.6%
2024
2024
2024
50%1,207,835261,55040,369986,654221,1812026
40%*966,268633,19712,571345,642620,6262026
10%241,56721,3008,308228,57512,9922026
2,415,670916,04761,2481,560,871854,799
* 2023
20212202122
Gaoling Fund L.P.YHG Investment L.P.Vivo Opportunity Fund, L.P.210,508,000
16.33%
14.04%14.45
421.023,041.44210,508,000
14.45202122
15.72
3,041.843,041.442021210
20246302024112024
2024
(i)
IND
1(1)
2,488244,463
2027
(ii) 23,731662,180
(iii) 156273,349(iv) 53,125775,406
3,041,4401,165,54279,5001,955,3981,086,042
1. 202122
20229212,919.07
140.25
2,778.82
202291620229162024630
2024112024
2024
1,494,220.61,242,867.387,134.1338,487.41,155,733.22027116,146.625,878.13,960.394,228.821,917.82027273,851.4159,144.716,499.4131,206.1142,645.3202760,952.332,296.13,089.331,745.529,206.82027833,644.7364,916.3167,633.8636,362.2197,282.52027
2,778,815.61,825,102.5278,316.91,232,030.01,546,785.6
2024630
20242023
419,738377,549(60,140)(76,072)
359,598301,477
111,356131,265(157,153)(191,208)(420,822)(358,130)(91,511)(87,299)(33,059)(179,150)(23,663)(23,707)(668)—(1,536)(2,087)(10,465)(20,345)
(267,923)(429,184)
(29)—
(267,952)(429,184)
(261,840)(422,211)
(6,112)(6,973)
(267,952)(429,184)
(0.16)(0.25)
2024630
20242023
(267,952)(429,184)
36,331233,692
36,331233,692
(231,621)(195,492)
(225,509)(188,519)
(6,112)(6,973)
(231,621)(195,492)
2024630
202420236301231
805,161759,764
296,546293,8373,1253,12536,54439,0074,1245,660
401,016—59,03352,413
1,605,5491,153,806
118,381119,095
280,677307,638
124,881113,994
642,941—6,903,6938,224,596
8,070,5738,765,323
117,242134,905
669,052667,717
5,0005,00011,27412,00834,18323,233
1,274,7941,251,131
2,111,5452,093,994
5,959,0286,671,329
7,564,5777,825,135
202420236301231
33,90026,30039,78143,647
294,048305,577
258,369268,906
626,098644,430
6,938,4797,180,705
2323(7,386)—6,919,0977,147,825
6,911,7347,147,848
26,74532,857
6,938,4797,180,705
20246301.
2015113
Ogier Global (Cayman) Limited, 89 Nexus Way, Camana Bay,Grand Cayman KY1-9009 Cayman Islands
20203232022921
2.
2024630
20231231
3.
202312
2020
2022
(a) 16—
—
(b) 2020
2022
2023202411
(c) 77
4.
(a)
20242023
418,080322,2341,65855,315
419,738377,549
(b)
2024
20231231
1,159,8191,146,19336,858414
1,196,6771,146,607
10%
20242023
A187,063102,863B47,42660,722C—55,315D37,58543,363
272,074262,263
5.
20242023
419,738377,549
(a)
20242023
417,820321,46695555,315963768
419,738377,549
418,080322,234
1,65855,315
419,738377,549
20242023
418,783322,234
95555,315
419,738377,549
(b)
3090
20242023
11,45029,20194,55993,771
—4068,2904,3383
111,356131,265
6.
20242023
31,03128,25514,03611,870
3,0212,66923,66323,707
(348)44,918
287,898251,066402,493337,32260,14076,07233,005178,6447.
16.5%202316.5%
2,000,00020232,000,000
8.25%20238.25%16.5%2023
16.5%
25%
15%202315%
25%30%
30%202330%
21%202321%
20242023630
20242023
—
8.
202463020236
9.
20242023
(261,840)(422,211)
20242023
1,688,2941,684,883
20242023630
20242023630
20242023630
10.
202463084,030,000202363090,900,000
202463035,00020236304,000
11.
2024
20231231
281,746276,778
—31,261(1,069)(401)
280,677307,638
2021
2024
20231231
268,816248,942
11,86158,696
280,677307,638
2024
20231231
401132668268
—
1,069401
12.
2024
20231231
64,35339,04444,57262,54014,63310,3901,3232,020
124,881113,994
202463020231231
13.
2024
20231231
102,521124,207
14,68610,432161991967
117,242134,905
14.
2024
20231231
1,274,7941,251,131
2023111,197,168
53,963
202312311,251,131
23,663
20246301,274,794
20188
9306.5%20241231
20248
15.
2024
20231231
11305,577287,761
14,03518,969(25,000)—
(564)(1,153)
294,048305,577
20211250,000,000
0.35%
20226325,000,0000.35%
2022620242
16.
2023A2023AA2015201620182020
20238112015201620182020
A0.000002AB0.000002B
20152015201696
183,888,050B2015
20152023811
20162016201696
22,200,000B2016
20162023811
2018201820181128
68,498,464B2018
2018202381120202020202073
102020
10%10%202020202023811
2023831
1051,481,607B
20242023
110.144023,7480.143329,833
0.17802,7900.17801,110
0.1780(4,240)0.1780(430)
——
0.1591(8,018)
6300.141822,2980.138722,495
2023630
1.0472
2024630
2,6500.000002202012252029811,4500.0552023916203191518,1980.17820229162034627
22,298
2023630
2,7700.0000022018962029811,9000.0552022316203191517,8250.1782020822033330
22,495
20242023(%)
62.1766.04
(%)
4.26–4.963.64–4.53
1010H
0.621.07
202463010.22202363043.1AA202362202362
A8,948,750
0.51%A
2024A1.292.4620235.496.532024630
9.872023630
1.8
Black-Scholes
20242023(%)
32.48–35.1830.63–35.68
(%)
1.66–2.011.97–2.33
2–52–5A
7.4412.28
A
20242023
116.957,090——
6.951,7376.957,209
6.95183
—
6306.958,6446.957,209
2024630
8,6446.952024622029530
17.
2024
20231231
43,58846,980
18.
(a)
20242023
11,96912,36610569(22,215)19,686
(10,141)32,121
(b)
*
* 2023714(c)
20242023
(i)
—
(i)—
54485
(ii)5378
(i)
(ii)(iii) 201614201888
20182016142020710
202020182020
2020(d)
2024
20231231
19.
202362A
2024620247111,634,75020247
794300794
20247
1,280,740,00020248
(www.hkexnews.hk)(www.innocarepharma.com)
D22024630
19DEL19AD
ALLAMLAQP4 IgG4ARRArriVentArriVent Biopharma
ASH
BBBCRT
B
BiogenBiogen Inc.BIIB
BTDBTKBTK
CD20BCD20MS4A1
BCDCCDENMPA
C1
CLLCNSL
99692015113
20203232022921
DLBCLB
DLT
EGFREULARFGFR
FL
GMP
20199
IBD
ICP-105ICP-192ICP-022IL-2-2IL-12-12IL-17-17IL-23-23IMiDIND
IRCITKTITPJAK
2020323
MCDB(DLBCL)
MYD88L265PCD79BMCD
MCLB
MOA
C3
MSMZL
NDABLANMOSD
NMPA
NRDLNSCLCNTRKFGFR(FGFR)TRK
PD
PK
2020311
R/Rr/rR-CHOP
RICE
264,648,2172022921
SC
0.000002
SHP2RAS
SLE
SLLSRISLE
T
TTBNKTDCCTTRK
TYK22UC
FDAFDA
VivoVivo Opportunity Fund, L.PVivo Capital VIII,
LLCWM
2024820